TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06123364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron 50 mg daily
Description: Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: mirabegron 50 mg daily
Description: Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal magnetic innervation (active treatment)
Description: Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive sham stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal magnetic innervation (sham treatment)
Description: Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive placebo stimulation.
Study: NCT01484314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
Study: NCT03044002

Intervention type: DEVICE
Intervention: Biotronik 4 French Portfolio
Description: Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease

Intervention type: DEVICE
Intervention: 6 French Portfolio
Description: Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
Study: NCT04613622

Intervention type: DRUG
Intervention: Venetoclax
Description: This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
Study: NCT02981537

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: two-staged endobronchial blocker insertion
Description: positioning endobronchial blockers in two-staged method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: two-staged endobronchial blocker insertion
Description: positioning endobronchial blockers in two-staged method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single-staged endobronchial blocker insertion
Description: positioning endobronchial blockers in traditional single-staged method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-staged endobronchial blocker insertion
Description: positioning endobronchial blockers in traditional single-staged method
Study: NCT02381652

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Injection into the knee

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Injection into the knee

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Injection into the knee
Study: NCT04367363

Intervention type: BEHAVIORAL
Intervention: Social media & news consumption
Description: Daily reports of social media use and consumption, including reports on receiving and disseminating news articles related to the COVID-19 situation (e.g., how many messaging groups shared news on the outbreak, how many items related to the outbreak they forwarded to others, etc).
Study: NCT02125136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem/nab-Pac
Description: All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIFINOX
Description: All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle.
Study: NCT01593865

Intervention type: PROCEDURE
Intervention: BIMA Grafting
Description: Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.

Intervention type: PROCEDURE
Intervention: Left-only mammary artery grafting
Description: These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
Study: NCT04310683

Intervention type: OTHER
Group type: OTHER
Intervention: natural cycle for endometrium preparation
Description: patients will not use oral contraceptive drugs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hormone replaced cycle for endometrium preparation
Description: patients will receive oral contraceptive drugs for menstruation before embryo transfer
Study: NCT02205541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.~ECZ or placebo will be administrated intravenously as a 30-minute injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~ECZ or placebo will be administrated intravenously as a 30-minute injection
Study: NCT02696863

Intervention type: BEHAVIORAL
Intervention: questionnaire
Study: NCT02115334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: professional therapists delivering the PHPA
Description: PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
Study: NCT04588727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3366
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3366
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: In Part B, subjects will receive oral ticagrelor tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor
Description: In Part B, subjects will receive oral ticagrelor tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA)
Description: In Part B, subjects will receive oral ASA chewable tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetylsalicylic acid (ASA)
Description: In Part B, subjects will receive oral ASA chewable tablets.
Study: NCT02645552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium Chloride solution (0.9%) 1 ml (gram) in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
Study: NCT04940520

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Drug recommended by the Brazilian Society of Dermatology
Description: Using a drug recommended by the Brazilian Society of Dermatology, twice a day.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha bisabolol product and laser
Description: Using alpha bisabolol-based product associated with low-level laser therapy. Alpha bisabolol-based product will be used twice a day, and laser therapy used once every fortnight.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alpha bisabolol product
Description: Using alpha bisabolol-based product twice a day
Study: NCT00334802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)~Phase 2: dose determined by phase 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles~Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles
Study: NCT04840459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAMLANIVIMAB
Description: n. Bamlanivimab is a recombinant neutralizing human mIgG1? monoclonal antibody (mAb) to the spike protein of SARS-CoV-2, and is unmodified in the Fc region.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CASIRIVIMAB
Description: CASIRIVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMDEVIMAB
Description: IMDEVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
Study: NCT06173739

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical mechanical treatment
Description: Nonsurgical mechanical therapy (NSMT) aims to control infection and minimize bacterial burden through debridement of the implant surface. It is the gold standard treatment method for both peri-implantitis and peri-implant mucositis.~Non-surgical mechanical treatment will be applied to patients with the purpose of surface debridement and reducing bacterial flora in implants with peri-implant disease for which clinical examination has been completed and the diagnosis has been confirmed. All intraoral implants of the patients will be evaluated and all implants that do not meet the clinical definition of health will be intervened. Each implant surface will be treated with a titanium curette. In all groups, mechanical debridement was performed on the surfaces by the same clinician.~The procedure will continue gently until it is felt that it has been adequately debrided. Subgingival irrigation will be performed with physiological saline. Post NSMT No medication will be administered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical mechanical treatment
Description: Nonsurgical mechanical therapy (NSMT) aims to control infection and minimize bacterial burden through debridement of the implant surface. It is the gold standard treatment method for both peri-implantitis and peri-implant mucositis.~Non-surgical mechanical treatment will be applied to patients with the purpose of surface debridement and reducing bacterial flora in implants with peri-implant disease for which clinical examination has been completed and the diagnosis has been confirmed. All intraoral implants of the patients will be evaluated and all implants that do not meet the clinical definition of health will be intervened. Each implant surface will be treated with a titanium curette. In all groups, mechanical debridement was performed on the surfaces by the same clinician.~The procedure will continue gently until it is felt that it has been adequately debrided. Subgingival irrigation will be performed with physiological saline. Post NSMT No medication will be administered.
Study: NCT00432315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + CDDP
Description: * 3 cycles chemotherapy : docetaxel + CDDP~* Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~* 3 cycles adjuvant chemotherapy docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel + CDDP
Description: * 3 cycles chemotherapy: docetaxel + CDDP~* Radiochemotherapy~* 3 cycles adjuvant chemotherapy docetaxel
Study: NCT02811497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study: NCT01746238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous infusion, every 2 weeks, 3 doses total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Daily, Monday-Friday, for 6 weeks
Study: NCT01350440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Intravenous Immune Globulin
Study: NCT01346540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: VEGF inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BIBF 1120 placebo
Study: NCT00110916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular metHuIL-1ra (anakinra)
Description: anakinra

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05771818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Falls Prevention Program
Description: The intervention consists of 10 sessions. One session a week consists of obstacle course training. The other session focuses on falls strategies training and walking and balance exercises. Each session lasts approximately 1.5 hours.
Study: NCT03747302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Media Message about HPV and HPV vaccine
Description: Messages educate parents with facts about HPV vaccination.

Intervention type: OTHER
Group type: OTHER
Intervention: Social media message about risk of electronic cigarettes.
Description: Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.
Study: NCT01714609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib, 400 mg twice daily
Study: NCT02172040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Over-encapsulated 10 mg amlodipine besylate tablet
Description: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
Study: NCT02115334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parents executing the PHPA
Description: PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health education
Description: health education of the children with DD.
Study: NCT03047902

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 - Parents will be present for the Questionnaire.
Description: In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.~In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2- Parents will not be present for the Questionnaire
Study: NCT01099683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Single rectal administration of 2 mg NRL001 in a 2 g suppository

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will receive rectal suppository containing placebo
Study: NCT03305471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2330b PIB
Description: DS-2330b as powder in bottle with stock solution (PIB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2330b PIB
Description: DS-2330b as powder in bottle with stock solution (PIB)
Study: NCT02172040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Over-encapsulated 10 mg amlodipine besylate tablet
Description: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched placebo capsule for over-encapsulated celecoxib capsule
Description: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Matched placebo capsule for over-encapsulated celecoxib capsule
Description: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Over-encapsulated 200 mg celecoxib capsule
Description: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Over-encapsulated 200 mg celecoxib capsule
Description: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo capsule for over-encapsulated amlodipine besylate tablet
Description: Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Matched placebo capsule for over-encapsulated amlodipine besylate tablet
Description: Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks
Study: NCT03305471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2330b PIB
Description: DS-2330b as powder in bottle with stock solution (PIB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2330b PIB
Description: DS-2330b as powder in bottle with stock solution (PIB)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching stock solution in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching stock solution in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Description: Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Description: Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Description: Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2330b Tablet
Description: DS-2330b as tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2330b Tablet
Description: DS-2330b as tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2330b Tablet
Description: DS-2330b as tablet formulation
Study: NCT02186314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Biotronik: apical stimulation
Description: Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Biotronik: apical stimulation
Description: Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Biotronik: bifocal stimulation
Description: Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Biotronik: bifocal stimulation
Description: Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker